Protagonist Therapeutics, Inc.
(NASDAQ : PTGX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. -1.28%569.282.7%$666.01m
ILMNIllumina, Inc. -0.29%319.513.5%$656.56m
AMGNAmgen, Inc. -1.22%228.281.3%$591.90m
ARRYArray BioPharma Inc. 3.53%39.8614.2%$519.90m
GILDGilead Sciences, Inc. -0.62%60.181.0%$503.92m
MRNAModerna, Inc. -2.45%69.570.0%$491.40m
VRTXVertex Pharmaceuticals, Inc. -2.00%210.241.9%$470.03m
IMMUImmunomedics, Inc. 0.10%87.8111.0%$388.16m
NVAXNovavax, Inc. -6.16%92.3096.5%$305.97m
ALXNAlexion Pharmaceuticals, Inc. -3.26%119.962.0%$288.02m
BIIBBiogen, Inc. -0.94%264.621.6%$255.20m
EXASEXACT Sciences Corp. -2.27%100.6920.7%$224.15m
BNTXBioNTech SE -6.89%87.850.0%$209.91m
SRNESorrento Therapeutics, Inc. -3.83%7.911.4%$185.32m
SGENSeagen Inc. 0.53%199.076.0%$170.99m

Company Profile

Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.